On Topic Virtual Roundtable: Nursing Strategies to Improve the Outcomes of Patients Receiving Cellular Therapy for the Treatment of Hematologic Malignancies
Release Date: February 28, 2022
Expiration Date: February 27, 2023
The estimated time to complete this enduring material is 45 minutes.
This enduring material is intended for nurses, advanced practitioners (NP/PA), and other healthcare providers who treat patients with hematologic malignancies
At the conclusion of this enduring material, the participants should be better able to:
- Explain the rationale for targeting CD19, BCMA, and other targets with cellular-based therapies for patients with hematologic malignancies
- Assess the results of the latest clinical trial data of current and emerging cellular therapies in patients with lymphoma and multiple myeloma
- Develop strategies that maximize the outcomes of patients receiving cellular therapy, including approaches that mitigate adverse events and maximize patient quality of life
- Discuss the value of team communication and in the inclusion of the patient as part of the team
Sherry Adkins, RN, MSN, CNS, ANP-C
Advanced Practice Provider Supervisor, Lymphoma Research
The University of Texas
MD Anderson Cancer Center
Faculty and Patient Advocate
Heather DiFilippo, MSN, CRNP
Bone Marrow Transplant and Cellular Therapy
The Hospital of the University of Pennsylvania
Nina Shah, MD
University of California San Francisco
San Francisco, California
Tomas Sandoval IV
CAR T-cell Therapy Survivor and Patient Advocate
Requirement for Successful Completion
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
- View the entire presentation
- Complete the post-test with a score of 75% or better
- Complete the online evaluation
Save and print your certificate. Retain for future documentation. Certificates are available post activity upon completion of the evaluation and attestation.
Accredited Continuing Education
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Nebraska Medical Center designates this activity for 0.75 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.
All faculty, planners, and others in a position to control continuing education content participating in a UNMC accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles (*indicates both faculty and planning committee member).
Nina Shah, MD*
Consultant Fees: Amgen, Bristol Myers Squibb, CareDx, GlaxoSmithKline, Indapta Therapeutics, Karyopharm, Kite, Sanofi
Research Support: Bluebird Bio, Celgene/BMS, Janssen, Nektar, Poseida, Sutro Biopharma, Teneobio
Tomas Sandoval IV*
Patient Experience Consultant: Novartis
Nina Shah, MD*
CAR T therapy and t cell engager therapy in myeloma
The below faculty have nothing to disclose
Sherry Adkins, RN, MSN, CNS, ANP-C*
Heather DiFilippo, MSN, CRNP*
Sara Fagerlie, PhD, CHCP
Consultant: Adaptive Biotechnologies
The following planning committee members have nothing to disclose:
UNMC: Anji Heath; Heidi Keeler, PhD, RN; Renee Paulin, MSN, RN, CWOCN
Bio Ascend: Chloe Dunnam; Aimee Harwood; Alison Heintz; Lacey Schmeidler; Kraig Steubing; Jenna Parker
Support for this educational activity provided by Bristol-Myers Squibb.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.